Your browser doesn't support javascript.
loading
First line therapy for patients with newly diagnosed multiple myeloma ineligible for autologous stem cell transplantation: a systematic review and meta-analysis (hemo-oncolgroup study)
Rodríguez, Myriam Riam Lucia; Combariza, Juan; Casas, Claudia Patricia; Reveiz, Ludovick; Buendía, Jefferson; Carvajal, Arturo Marti; Ramírez, Henry Becerra; Cardona, Andrés Felipe.
  • Rodríguez, Myriam Riam Lucia; Fundação Sante Fé de Bogotá. Departamento de Hematologia de terapia de medula óssea. Bogotá. CO
  • Combariza, Juan; Hospital Pablo Tobón Uribe. Departamento de Hematologia e Transplante de Medula Óssea. Medellin. CO
  • Casas, Claudia Patricia; Instituto Nacional de Cancerologia. Departamento de Hematologia e Transplante de Medula Óssea. Bogotá. CO
  • Reveiz, Ludovick; Universidade Nacional da Colômbia. Instituto de Pesquisa Clínica. Bogotá. CO
  • Buendía, Jefferson; Universidade Nacional da Colômbia. Instituto de Pesquisa Clínica. Bogotá. CO
  • Carvajal, Arturo Marti; Rede Cochrane Ibero-americana. Valencia. VE
  • Ramírez, Henry Becerra; Universidade Nacional da Colômbia. Faculdade de Medicina. Bogotá. CO
  • Cardona, Andrés Felipe; Fundação Sante Fé de Bogotá. Grupo de oncologia clínica e translacional. Bogotá. CO
Appl. cancer res ; 32(4): 122-141, 2012. tab
Artículo en Inglés | LILACS, Inca | ID: lil-706011
ABSTRACT

Background:

Patients not eligible for stem cell transplantation (SCT) have been treated with melphalan (M) plus prednisone (P); however, the standard of care has shifted to MP plus thalidomide(T) due to a greater survival benefit. Bortezomib (B) and lenalidomide have also emerged as effective agents.

Methods:

Randomized clinical trials (RCTs) that compared MP to any otherregimen were identified from the databases of Cochrane Library, PubMed, LILACS, EMBASE and Scirus.

Results:

Twenty-two trials were included from 2159 potential eligible references. MP vs.M plus dexamethasone (MD) (3 RCTs) MD was superior in partial response (PR) rate and non-hematological toxicity. MP vs. T-based regimens (4 RCTs) significant differences favoring T-basedregimens in complete response (CR) rate, partial response (PR) rate, and progression-free survival (PFS). MP vs. B based regimens (1 RCT) significant differences in overall survival (OS) , time to progression (TTP), CR and PR rate favored B-based regimens according to the European Group for Blood and Marrow Transplantation (EBMT) criteria. MP vs. chemotherapy regimens withoutM (3 RCTs) A significantly higher number of patients treated with BP achieved a CR. TTP was alsosignificantly longer in BP-treated patients (p < 0.02). MP vs. other polychemotherapy regimens(13 RCTs) No significant differences in PR, OS, hematological or other type of toxicity were observed between MP and the other chemotherapy regimens.

Conclusions:

Symptomatic multiplemyeloma patients ineligible for SCT should receive as first-line treatment a combination of MP plus B or T; these regimens are associated with improved outcome but greater toxicity comparedto MP alone. More homogeneous clinical trials using a cytogenetic risk approach are required
Asunto(s)

Texto completo: Disponible Índice: LILACS (Américas) Asunto principal: Trasplante Autólogo / Metaanálisis como Asunto / Quimioterapia / Mieloma Múltiple Tipo de estudio: Ensayo Clínico Controlado / Estudio diagnóstico / Estudio pronóstico / Revisiones Sistemáticas Evaluadas Límite: Humanos Idioma: Inglés Revista: Appl. cancer res Asunto de la revista: Neoplasmas Año: 2012 Tipo del documento: Artículo País de afiliación: Colombia / Venezuela Institución/País de afiliación: Fundação Sante Fé de Bogotá/CO / Hospital Pablo Tobón Uribe/CO / Instituto Nacional de Cancerologia/CO / Rede Cochrane Ibero-americana/VE / Universidade Nacional da Colômbia/CO

Similares

MEDLINE

...
LILACS

LIS

Texto completo: Disponible Índice: LILACS (Américas) Asunto principal: Trasplante Autólogo / Metaanálisis como Asunto / Quimioterapia / Mieloma Múltiple Tipo de estudio: Ensayo Clínico Controlado / Estudio diagnóstico / Estudio pronóstico / Revisiones Sistemáticas Evaluadas Límite: Humanos Idioma: Inglés Revista: Appl. cancer res Asunto de la revista: Neoplasmas Año: 2012 Tipo del documento: Artículo País de afiliación: Colombia / Venezuela Institución/País de afiliación: Fundação Sante Fé de Bogotá/CO / Hospital Pablo Tobón Uribe/CO / Instituto Nacional de Cancerologia/CO / Rede Cochrane Ibero-americana/VE / Universidade Nacional da Colômbia/CO